TW200942614A - Composition for modulating stem cell growth - Google Patents

Composition for modulating stem cell growth

Info

Publication number
TW200942614A
TW200942614A TW098105222A TW98105222A TW200942614A TW 200942614 A TW200942614 A TW 200942614A TW 098105222 A TW098105222 A TW 098105222A TW 98105222 A TW98105222 A TW 98105222A TW 200942614 A TW200942614 A TW 200942614A
Authority
TW
Taiwan
Prior art keywords
composition
stem cell
cell growth
modulating
modulating stem
Prior art date
Application number
TW098105222A
Other languages
English (en)
Chinese (zh)
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of TW200942614A publication Critical patent/TW200942614A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW098105222A 2008-02-19 2009-02-19 Composition for modulating stem cell growth TW200942614A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2971308P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
TW200942614A true TW200942614A (en) 2009-10-16

Family

ID=40602552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098105222A TW200942614A (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth

Country Status (16)

Country Link
US (2) US8871752B2 (enExample)
EP (2) EP2656845A1 (enExample)
JP (1) JP2011512323A (enExample)
KR (1) KR20100119803A (enExample)
CN (2) CN102014921A (enExample)
AR (1) AR073158A1 (enExample)
AU (1) AU2009216067B2 (enExample)
BR (1) BRPI0907831A2 (enExample)
CA (1) CA2715486A1 (enExample)
IL (1) IL207652A0 (enExample)
MX (1) MX2010009131A (enExample)
NZ (1) NZ587348A (enExample)
RU (1) RU2010138603A (enExample)
TW (1) TW200942614A (enExample)
WO (1) WO2009104807A1 (enExample)
ZA (1) ZA201006125B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533445A1 (en) * 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
KR101171912B1 (ko) 2010-11-29 2012-08-07 기아자동차주식회사 밸브브릿지 일체형 가변 밸브 액츄에이터
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US20140371304A1 (en) * 2013-06-13 2014-12-18 Sucampo Ag Method for suppressing tumorigenicity of stem cells
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
AU2018280264B2 (en) 2017-06-09 2024-07-11 Myoforte Therapeutics, Inc. Compositions and methods for preventing or treating muscle conditions
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
AU2001239551B8 (en) * 2000-03-24 2005-11-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
JP4557288B2 (ja) * 2005-01-28 2010-10-06 アイシン・エィ・ダブリュ株式会社 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置
EP1853271B1 (en) * 2005-03-04 2010-12-01 Sucampo AG Method and composition for treating peripheral vascular diseases
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2007070964A1 (en) 2005-12-22 2007-06-28 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2008108322A2 (en) 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
FI20075417A0 (fi) 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen

Also Published As

Publication number Publication date
WO2009104807A1 (en) 2009-08-27
MX2010009131A (es) 2010-12-06
RU2010138603A (ru) 2012-03-27
CN102014921A (zh) 2011-04-13
BRPI0907831A2 (pt) 2017-04-11
IL207652A0 (en) 2010-12-30
CA2715486A1 (en) 2009-08-27
KR20100119803A (ko) 2010-11-10
NZ587348A (en) 2012-04-27
JP2011512323A (ja) 2011-04-21
EP2656845A1 (en) 2013-10-30
US20150005381A1 (en) 2015-01-01
AU2009216067A1 (en) 2009-08-27
AR073158A1 (es) 2010-10-20
US20090209643A1 (en) 2009-08-20
CN104248638A (zh) 2014-12-31
ZA201006125B (en) 2011-05-25
US8871752B2 (en) 2014-10-28
EP2303278A1 (en) 2011-04-06
AU2009216067B2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
TW200942614A (en) Composition for modulating stem cell growth
EP4296270A3 (en) A composition comprising stem cell cultures
MX356756B (es) Células madre pluripotentes en microportadores.
MY159971A (en) Multipotent/pluripotent cells and methods
WO2010111422A3 (en) Induced pluripotent stem cell generation using two factors and p53 inactivation
WO2010129294A3 (en) Small molecules supporting pluripotent cell growth and methods thereof
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
SG170021A1 (en) Compositions and methods useful for culturing differentiable cells
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
AU2007230902A8 (en) Method to modulate hematopoietic stem cell growth
PH12013500827A1 (en) Chromobacterium bioactive compositions and metabolites
EP2046946B8 (en) Pluripotent stem cell culture
WO2012003479A3 (en) Methods for culturing undifferentiated cells using sustained release compositions
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
WO2012142569A3 (en) Decellularized extracellular matrix
EP4368701A3 (en) Feeder-free culture system
GB2454386A (en) Method for stem cell culture and cells derived therefrom
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
SG148171A1 (en) Methods of proliferating stem cells
IL246057A (en) Peptide-presenting surfaces for long-term culture of multi-potential cells
MX2010007945A (es) Preparacion y transplante de celulas de isletas pancreaticas.
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
MX2012002013A (es) Moduladores de activador del factor de crecimiento de hepatocitos.
EP2001993A4 (en) INCREASING CELL CULTURE DOUBLES FOR LONG-TERM GROWTH OF CELLULAR CULTURES WITH A DETERMINED LIFETIME
PH12014500304A1 (en) Enzyme system